We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Assura Plc | AGR | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.02 | -0.05% | 41.62 | 16:35:03 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 41.60 | 41.38 | 42.34 | 41.62 | 41.64 |
| Industry Sector |
|---|
| FOOD & DRUG RETAILERS |
| Top Posts |
|---|
Posted at 16/4/2024 19:16 by grahamite2 alotto, you might find this interesting:If Barclays is claiming the tax back for you, they are going the extra mile. My tax deducted is dealt with in my tax return. |
Posted at 10/1/2024 07:54 by cwa1 Trading update:-Trading Update For the third quarter ending 31 December 2023 Assura plc ("Assura"), the leading primary care property investor and developer, today announces its Trading Update for the third quarter to 31 December 2023. Jonathan Murphy, CEO, said: "Assura has delivered another quarter of disciplined activity to further enhance our growing portfolio, with our market-leading position and strong balance sheet seeing us well-placed for the long-term. "Alongside completing two asset enhancement projects in the period, we continued to leverage our proven track record and market expertise to respond to distinct challenges and provide quality capacity for services in a community setting. We see opportunities to respond to this healthcare challenge by developing for private providers, working directly with NHS Trusts and mental health services as well as bringing our expertise to the Irish market. "We completed a state-of-the-art cancer treatment centre in Guildford which will provide highly advanced oncology treatments to both NHS and private patients; and moved on site to double the size of our community care centre in Castlebar, Ireland - a market for which we have three schemes in our immediate development pipeline. "The need for high-quality, sustainable healthcare buildings in a community setting is unabated, and Assura remains best-placed to meet the demands of an ageing population and growing pressures on the health system at a time when one-third of the UK's current GP estate is in need of replacement." Disciplined investment activity further enhancing our attractive and resilient portfolio · Portfolio of 612 properties across the UK and Ireland with an annualised rent roll of £148.6 million · Successful completion of £30 million state-of-the-art cancer care facility in Guildford, increasing capacity for treatment of NHS and private patients in the area · Moved on site with significant development project in Castlebar, Ireland doubling the size of the facility to create an Enhanced Community Care Centre as well as substantially improving sustainability performance targeting operational energy usage intensity of 55 kWh/m2 · Disposed of one property for £1.2 million · Completed two asset enhancement capital projects (total spend £4.9 million), including large extension project at Wantage Health Centre (increasing capacity, refurbishing the existing space and upgrading the building to EPC B) · 46 rent reviews settled in the quarter, covering £3.8 million of existing rent and generating an uplift of £0.6 million · EPC improvement programme continues: 17 properties upgraded to EPC B in the quarter, 58% of portfolio now at EPC B or better Pipeline of emerging opportunities for strategic expansion and further growth · Currently on site with nine developments; these have a remaining spend over the next 18 months of £36 million of a total cost of £91 million (September 2023: 10 on site, £114 million total cost) · Immediate development pipeline of four schemes (UK: one, Ireland: three), where we would normally expect to be on site within 12 months; total cost of £28 million (September 2023: four, £25 million). We continue to experience delays on pipeline schemes in the UK as we negotiate to ensure rents appropriately reflect the current cost of construction. · On site with five asset enhancement capital projects (total spend of £2.7 million over the next 12 months); pipeline of 17 asset enhancement capital projects (projected spend £10.6 million) over the next two years · 43 lease re-gears covering £8.1 million of existing rent roll in the current pipeline Robust financial position and strong balance sheet · A- (stable outlook) credit rating from Fitch Ratings affirmed in January 2024 · Weighted average interest rate unchanged at 2.30% (September 2023: 2.30%); all drawn debt on fixed rate basis · Weighted average debt maturity of 6.25 years, no refinancing on drawn debt due until October 2025. Over 50% of drawn debt matures beyond 2030, with our longest maturity debt at our lowest rates · Revolving credit facility refinanced as previously announced, increasing to £200 million, reducing the overall cost and adding sustainability-linke · Net debt of £1,214 million on a fully unsecured basis with cash and undrawn facilities of £238 million |
Posted at 14/12/2023 16:59 by goliard One thing that annoys me here is the scrip dividend. In thoery you can choose to receive shares for the value of the dividend and the scrip price is now set at 43.94p. You then have until 28 December to make the choice, so if the share prices rises, you can choose shares instead of cash which is what I would like to do as it is an easy profit and relatively low risk.However, you can only use the scrip dividend if you are an institution or have your own CREST account, or if you have old fashioned share certificates. I cannot do that with my holding as it is with Interactive Investor and AJ Bell. I do wish they would sort that out or has anyone else found a way to do it? I tried and failed. EDIT 8 January 2024 - so about 25% of shares elected for the scrip and take a significant % increase in value of their dividend that way. No wonder institutions like this as their yield is significantly increased as the expense of those who cannot or do not elect to have the scrip alternative. |
Posted at 10/7/2023 05:36 by grahamite2 Shore Capital: Assura offers confidence in future dividendsProperty business Assura (AGR) has a business model that is offering long-term attractions, says Shore Capital. Analyst Andrew Saunders reiterated his ‘buy’ recommendation on the developer of medical centres, which fell 1.1%, or 0.5p, to 44.4p on Friday. A quarterly trading update from the group confirmed ‘good progress with its programme of new development and asset enhancement’. ‘Assura’ He said that the Assura ‘operating model offers several long-term attractions that should help underpin investor confidence in future dividend payments’. ‘Assura’ |
Posted at 31/1/2023 12:52 by speedsgh Share tip: Assura, the fallen angel that can soar again - Small wasn’t beautiful for parts of the stock market in 2022: broker Numis’s small-cap index lost almost 20 per cent last year. The tiddlers on its list were joined by 45 firms that shrank enough to slip down from larger categories — “fallen angels”, in Numis’s words. Investors had backed away amid fears about the durability of profits and dividends. Assura, the GP surgery landlord, was one of those fallers. The FTSE 250 investment trust — which buys, builds and manages community healthcare buildings — has been a victim of rising interest rates. Its shares fell a fifth in 2022, giving a £1.6 billion market cap, and are now changing hands at 55.5p. And aside from the firm’s own fortunes, it might seem a questionable time to invest in the NHS (which underpins 81 per cent of Assura’s income) given the anger among healthcare staff. But the other spin, as chief executive Jonathan Murphy puts it, is that the pressures on the NHS [mean] “the need to invest in high-quality primary care to help alleviate this has never been greater.” In this light, Assura still seems a good long-term bet — indeed, the NHS’s capital guidance plan for 2022-25 includes £100 million for investment in primary care estates plus IT. The Cheshire-based firm has a portfolio of 607 properties valued at £2.7 billion, and the GPs and other care providers who lease properties from it pay annualised rent worth some £141 million. Its balance sheet shows cash and undrawn debt facilities of £255 million, and net debt of £1.1 billion (all of which is fully hedged). The firm is conservatively run — at the end of last year, Murphy said it would “proceed cautiously with deploying capital” in the short term. Although demand for healthcare won’t diminish in a downturn, rising costs and government spending cuts are a concern, and so it trimmed its M&A spending plans. Assura’s focus on primary healthcare means it is more resilient than other property stocks, and NHS trends look positive for investments in GP surgeries and pharmacies, where patients can be treated more cheaply than in hospitals. In the six months to September 2022, Assura’s net rental income rose by 15 per cent to £70 million, although it reported a £19 million valuation loss, mostly due to the gilts market. Its total property return fell to 1.8 per cent for the six months, down from 3.5 per cent in 2021. This investment might require patience, but the price-to-earnings ratio, which has hovered in the mid-20s for the past five years, is now 18. Long-term patient trends, and the likely political direction, make Assura a buy. |
Posted at 01/12/2022 07:53 by cwa1 Notice of DividendAssura plc ("Assura" or "the Company"), the UK's leading primary care property investor and developer, today announces that the next quarterly interim dividend of 0.78 pence per share will be paid on 11 January 2023 to shareholders on the register on 9 December 2022 (the "Record Date"). The Ex-dividend Date will be 8 December 2022. This interim dividend will be a normal dividend (non-PID). Please refer to Company's website HERE for more information |
Posted at 01/9/2022 07:10 by cwa1 Assura plc ("Assura" or "the Company"), the UK's leading primary care property investor and developer, today announces that the next quarterly interim dividend of 0.78 pence per share will be paid on 12 October 2022 to shareholders on the register on 9 September 2022 (the "Record Date"). The Ex-dividend Date will be 8 September 2022. |
Posted at 31/5/2022 07:19 by cwa1 Notice of DividendAssura plc ("Assura" or "the Company"), the UK's leading primary care property investor and developer, today announces that the next quarterly interim dividend of 0.78 pence per share will be paid on 13 July 2022 to shareholders on the register on 10 June 2022 (the "Record Date"). The Ex-dividend Date will be 9 June 2022. |
Posted at 20/2/2022 15:43 by tole My favourite penny stock to buy right now for incomeRupert Hargreaves | Sunday, 20th February, 2022 | More on: AGRPiggy bank group pastel color background Image source: Getty ImagesMy favourite penny stock to buy right now is also an income champion. What's more, while it qualifies as a penny stock, the company has a market capitalization of £1.6bn. This suggests the business has fewer risks than smaller enterprises, which usually fall into the penny share bracket. The company I am talking about is Assura (LSE: AGR). The corporation is a leading primary care property investor and developer. It owns an expanding portfolio of 634 properties in the healthcare sector across the UK. Defensive sector Healthcare is one of the most defensive sectors on the stock market. Property is also generally considered to be a defensive sector. The healthcare property sector combines the benefits of both. Most healthcare facilities are constructed to a specific standard, and they are let on extended leases to providers such as the NHS. With its steady, predictable income stream from the property portfolio, the penny stock has become an income champion over the past five years. At the time of writing, the stock supports a dividend yield of 5%. The payout has grown at a compound annual rate of 5% over the past six years as the company has increased the size of its property portfolio and expanded the rent roll. Assura's management plans to grow the portfolio further over the next couple of years. It has a development pipeline of 22 new schemes, and £71m of portfolio acquisitions were being negotiated at the beginning of the year. As the company has expanded, it has relied heavily on shareholders to provide additional capital. The average number of shares in issue has increased from 1.3bn in 2016 to 2.7bn. This dilution means that as the enterprise has increased the value of its portfolio by around 100% over the past six years, book value per share has risen by just 26%.The potential for further dilution is a significant risk facing investors. The company also has around £1bn of debt. The cost of this debt could increase with higher interest rates. Penny stock buy Despite these challenges, I think the healthcare facilities provider is one of the best investments to buy now for my portfolioIn fact, I think the business has fantastic potential over the next decade. Healthcare spending in the UK is only going to increase.The government has already laid out plans to open up more healthcare facilities across the country to deal with the current NHS backlog. This presents a fantastic opportunity for the group to acquire and build new facilities to meet the demand from the health service.With demand for these facilities set to grow in the years ahead, it looks as if Assura's dividend payout can continue to rise over the next decade and beyond. Considering its income and growth potential, I would be happy to buy the penny stock. |
Posted at 05/11/2021 08:18 by alter ego "Investor PresentationAssura plc ("Assura" or "the Company"), the UK's leading primary care property investor and developer, is pleased to announce that Jonathan Murphy (CEO) and Jayne Cottam (CFO) will host a live presentation relating to the Interim Results for the six months ended 30 September 2021 via the Investor Meet Company platform on Friday 12th November 2021 at 3.00pm GMT. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard until 9.00am the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and register to follow Assura plc via this link: Investors who already follow Assura plc on the Investor Meet Company platform will automatically be invited to the event." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
